Tag: Pakistan

Bedford, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Leveraging its robust phenolics platform, Conagen announced the expansion of the health ingredient portfolio of its commercial partner Blue California, with the successful scale-up and commercialization of the powerful natural antioxidant ingredient hydroxytyrosol.With its health-promoting properties, hydroxytyrosol is a phenylethanoid found in olives and wine. Most hydroxytyrosol is naturally found in the juice of olives, minorly in oil. Current hydroxytyrosol ingredients on the market are produced mainly through processed olive juice or are synthetic.

Conagen’s high-purity hydroxytyrosol is virtually colorless and odorless, making it ideal for formulating different products. The hydroxytyrosol is produced by using a cost-effective, sustainable natural fermentation process that has led to the filing of several patent applications, making it a preferred option compared to its olive juice concentrate and synthetic counterparts.

“Hydroxytyrosol is derived from one of our four small-molecule platforms.  The flexibility of our phenolics platform has enabled us to rapidly scale and commercialize hydroxytyrosol and other novel ingredients, highlighting our productive innovation engine and reliability as a strategic service partner,” said Vice President of Innovation, Casey Lippmeier, Ph.D. at Conagen.

Hydroxytyrosol has received increasing attention in the dietary supplement world due to its potent antioxidant and anti-inflammatory properties that contribute to the many health benefits of consuming olives. Preclinical and clinical studies demonstrate the positive effects of hydroxytyrosol on heart health and support healthy cholesterol levels.

“The Mediterranean diet is consistently rated as one of the healthiest diets, partially attributed to the use of olives,” Blue California’s Research, Science and Innovation Officer, Linda May-Zhang, Ph.D. “Hydroxytyrosol is one of the most potent antioxidants in olives, and research suggests the great promise of this molecule in healthy aging and potential immune support applications.”

In addition to immune health, emerging research suggests hydroxytyrosol supports heart health, metabolic health, bone health, brain health, and beauty.

Immune health will remain a top priority for consumers as 64% of global consumers are looking to improve their immunity over the next 12 months, reported by FMCG Gurus, Top Ten Trends for 2021, Dec. 2020.

“Conagen is unlocking unprecedented access to sustainable compounds which are only sparingly found in nature,” said Lippmeier. “We expect this and other related compounds will prove useful as cost-effective food or cosmetic ingredients or as additives to other products in which oxidation must be mitigated.”

Using precision fermentation, Conagen produces an extensive portfolio of ingredients, with a recent focus on phenolic antioxidants and natural preservatives such as Rosmarinic acid (Rosavel®), Capsaicin, and the recently announced p-Coumaric Acid (PCA). These ingredients add to a long list of health-promoting flavonoids such as Dihydroquercetin (DHQ), also known as Taxifolin.

Blue California is a provider of solutions and manufacturer/distributor of specialty ingredients, flavors, and fragrances and has a long-standing innovation partnership with Conagen. Conagen focuses on developing sustainable, nature-based ingredients that improve existing options in the market or represent completely novel ingredient solutions.

About Conagen

Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

Attachment

• hydroxytyrosol from olives

Ana Arakelian
Conagen
+1.781.271.1588
ana.arakelian@conagen.com

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

*Tune into Day 2 of the Summit at 13:00 GMT at essentialforrecovery.org*

London, UK, Sept. 09, 2021 (GLOBE NEWSWIRE) — Wednesday, Sept. 8 marked the opening day of the first-ever global summit of essential workers. Participants from around the world tuned in to a powerful conversation about an economic recovery that prioritizes essential workers, especially women in the informal economy.

“Universal social protections for essential workers are no longer a choice for governments; it is a very necessary move for governments to take,” Lorraine Sibanda, president of StreetNet International, an international alliance of street vendors, told the crowd.

The Essential for Recovery summit, which runs from September 8 through September 10, brings together essential workers from North and South America, Europe, Africa, and Asia with global business and government leaders to discuss a framework for a just economic recovery from the Covid-19 pandemic. The event centers the demands of care workers and the 61% of workers worldwide who labor in the informal economy, including domestic workers, agricultural workers, street vendors, and home-based workers.

“Home-based workers contribute around $300 billion to the economy, but they don’t get any benefit out of it. We are part of supply chains but we are not recognized as contributors to the supply chains,” said Saira Feroze of the Home-Based Women Workers Federation, on Day 1 of the summit.

The first day of the innovative summit brought together diverse voices from across the globe. Martha Chen, a lecturer at Harvard and senior advisor to Women in Informal Employement: Globalizing and Organizing (WIEGO), interviewed Rosheda Muller, president of the South African Informal Traders Alliance, on how street vendors are organizing globally. Legendary South African labor leader Myrtle Witbooi spoke with Maina Kiai, senior official at Human Rights Watch and former United Nations Special Rapporteur. And actor and activist Martin Sheen and actress Yalitza Aparicio made special appearances.

“COVID-19 taught us the importance of all workers in different sectors, recognizing that they deserve decent work and are important in the global economy. Governments know about this issue, but what are they doing about it?” asked Aparicio, who was nominated for an Oscar for her performance in the 2019 movie Roma.

Day 2 of the event on Thursday will focus on the fight against inequality, sexual harassment, and abuse in the workplace. Guests include: Rosa Pavanelli, the General Secretary of Public Services International, interviewing “Mama Union” Rose Omamo, leader of the Kenyan metal workers union; journalist Xanthe Scharff interviewing Mercedes D’Alessandro, feminist economist and Argentine government official; and journalist Reena Ninan interviewing business leader Brid Gould of Sodexo.

About Essential For Recovery:

The Essential for Recovery Summit is led by non-profit labor organizations — including  HomeNet International, International Domestic Workers’ Federation, International Trade Union Confederation, Solidarity Center, StreetNet International, UNI Global Union, and Women in Informal Employment: Globalizing and Organizing — and supported by the Open Society Foundations.

Communications
Open Society Foundations 
(212)-548-0378
media@opensocietyfoundations.org

QUEBEC CITY, Sept. 09, 2021 (GLOBE NEWSWIRE) — LeddarTech^®, a global leader in Level 1-5 ADAS and AD sensing technology, is pleased to announce its participation in several digital and in-person events during September in the capacity of both an exhibitor and presenter. These global events will showcase LeddarTech’s comprehensive end-to-end technology platforms, which enable customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility markets. These featured solutions include the LeddarVision™ sensor-fusion and perception platform and the cost-effective, scalable LiDAR development platform based on patented LeddarEngine™ technology.

“The acceleration of autonomous driving depends heavily on the ADAS solutions being developed today,” stated Daniel Aitken, VP of Global Marketing, Communications, and Product Management at LeddarTech. “These upcoming events highlight LeddarTech’s scalable and flexible reimagined approach with LiDAR and sensor-fusion and perception solutions that address individual customer needs,” he continued. “We are especially pleased to have Mike Thoeny, President of the Automotive Business Group at Flex, co-host one of our sessions. We look forward to you joining us for one or all of these events,” Mr. Aitken concluded.

Industry Tech Days – September 13-17 (Digital)

Industry Tech Days brings essential insights in electronics, everything from edge intelligence design to next-generation automotive sensors, delivered LIVE straight from industry experts to your desktop or mobile device.

Join LeddarTech for two presentations:

• “Sensor-Fusion and Perception Solutions for Key ADAS and AD Applications” (Use Case), featuring Youval Nehmadi, Engineering Director, LeddarTech Sensor Fusion and Perception Platform Research & Development Center, Israel.
• “Why Flexible Platforms Are Required for Future ADAS/AD Deployments,” by Frantz Saintellemy, LeddarTech’s President and COO, and Mike Thoeny, President of the Automotive Business Group at Flex.

Register for free here.

China International Optoelectronic Conference (CIOE) / MEMS Seminar – September 16-18 (Live in Shenzhen, China)

CIOE is China’s largest optoelectronic industry event, held in the Shenzhen World Convention and Exhibition Center. Mr. Horry Cheng will represent LeddarTech on the panel for “LiDAR and 3D Camera Sensing Technology & Applications,” and LeddarTech will also exhibit at this prestigious event.

Register here.

Automotive LiDAR Conference 2021 – September 21- 23 (Digital Event)

This conference is one of the only events exclusively focused on automotive LiDAR technologies and applications. The conference sessions will present the various approaches in developing a LiDAR system and explain the reasons for choosing one approach over another.

• Join LeddarTech’s CTO Pierre Olivier on September 21 at 2:00 p.m. EST for his featured presentation “Combining LiDAR, Radar, and Camera: Sensor Fusion Challenges and Solutions.”

Register here.

For a complete list of LeddarTech’s upcoming live and virtual events, please visit leddartech.com/events.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end-to-end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision™ sensor-fusion and perception platform and its cost-effective, scalable, and versatile LiDAR development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™, LeddarTech enables Tier 1-2 automotive system integrators to develop full-stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

SAN JOSE, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) will hold a Financial Analyst Briefing on September 13, 2021 during its premier customer event, Zoomtopia. The event will be hosted by members of the executive team and will cover Zoom’s business strategy, opportunities, and initiatives.

Attendees of the Financial Analyst Briefing must first register for Zoomtopia at: https://www.zoomtopia.com/. Once registered, attendees will receive instructions for joining the Zoomtopia lobby from where they may search for and join the Financial Analyst Briefing track. The live video webinar will begin at 2pm ET/11am PT, and last for approximately two hours. Attendees must update their Zoom client to version to 5.7.6 or later in order to run Zoom Events and join the session smoothly.

A replay will be available approximately three hours after the conclusion of the live event at https://investors.zoom.us/news-events/events.

About Zoom

Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Press Relations

Colleen Rodriguez
Global PR Lead for Zoom
press@zoom.us

Investor Relations

Tom McCallum
Head of Investor Relations for Zoom
408.675.6738
investors@zoom.us